The dual role of Toll-like receptor10

Motahareh Dargahi 1, Niloufar Taheri 1, Zahra Mirsanei 1, Arezoo Rasti 2, Reza Jafari 1*

1School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran.
2Department of Basic Sciences/ Medical Surgical Nursing, Faculty of Nursing and Midwifery, Tehran University of Medical Sciences (TUMS), Tehran, Iran.

*Corresponding Author: reza Jafari Email: rezajafari5599@gmail.com
Address: Shahroud University of Medical Sciences, Haft-e Tir SQ, Shahroud, Iran.
Tell: 00982332395054 Fax: 00982332395009 Postal Codes: 36147-73947

Abstract

Toll-like receptors (TLRs) are a class of pattern recognition receptors (PRRs) family that identify pathogen-associated molecular patterns (PAMPs) derived from microbes and activate immune cell responses. Following ligation of TLRs, different adaptor and transcription molecules such as myeloid differentiation primary response gene 88 (MyD88) and nuclear factor kappa B (NF-kB) are involved and trigger pro-inflammatory responses. The human Toll-like receptor 10 (hTLR10) is a novel member of the Pattern recognition receptors (PRRs) family. Its unique cytoplasmic domains lead to induction of both inflammatory and anti-inflammatory properties and thus regulates the function of immune responses. Recent studies have reported the association of TLR10 polymorphisms with many inflammatory diseases and human cancers. Despite the proven role of TLR10 in the induction of proinflammatory cytokines and chemokines, other studies have proven an anti-inflammatory role of TLR10. Accordingly, TLR10 suppresses proinflammatory cytokine production via negative regulation of MyD88 and the Akt (protein kinase B) and MAPK (mitogen-activated protein kinase) signaling pathways. This review aimed to provide answers for these conflicting findings (Inflammatory and anti-inflammatory properties of TLR10) to further identify distinct biological functions of TLR10.

Keywords: Toll-Like Receptor, Innate Immunity, Inflammation, Anti-inflammation
Introduction

Overview of TLR10

TLRs are highly conserved transmembrane proteins that are involved in innate immune responses through the recognition of variety of endogenous and exogenous stimuli (1, 2). They are mainly expressed on cells which act as antigen-presenting cells such as dendritic cells, and their signaling activity translates innate immunity to adaptive immunity (3). To date, 13 members of TLRs have been identified including TLR1–TLR10 in humans (4) and TLR1–TLR9, TLR11–TLR13 in mice (5). A novel toll-like receptor (TLR) was reported by Tsung-Hsien Chuang and Richard J.Ulevitch in 2001 and termed human TLR10 (6). Many studies reported that TLR10 is expressed in humans but not in mice (7-9). Although functional mouse homologue of hTLR10 has not yet been identified, it is reported the low level expression of TLR10 in Plasmacytoid dendritic cells (PDCs) from rat spleen (10, 11). Also, TLR10 protein is expressed by a retroviral sequence in mouse TLR10 gene (12). On the other hand, presence of hTLR10 (CD290) in human DNA genomes has been proven using the expressed sequence tag (EST) database of NCBI with a blast program (13). Protein analysis has shown that the structure of TLR4 is similar to other TLRs (14). The evolutionary relationship of 3 of the 10 members of the hTLRs suggested that they were more closely related to hTLR1 and hTLR6 compared to other TLRs (6, 15).

Many efforts have been made to identify the properties of TLR10, like its ligand and signaling pathway function. Some pathogen-associated molecular patterns (PAMPs) such as Listeria Monocytogenes and Salmonella Typhi murium (16), influenza viral (ribonucleoprotein RNP) (17), helicobacter pilory (18), and double strand RNA (dsRNA) (19) are introduced as a ligand for TLR10. TLR 10 remains the only orphan member among the human TLRs that is able to homodimerize or heterodimerize with TLR1 and TLR2 (20). Similar to other members of TLR family, hTLR10 contained the repeated leucine-rich (LRRs) domains, an extracellular cysteine-rich domain, and a transmembrane with a TIR domain (21). The crystal structure of the homodimer of hTLR10 revealed cytoplasmic toll/IL-1 receptor (TIR) domain (22). The overall structure of TIR domains is largely the same between TLR members (23). However, TIR domain orientation of TLR2/TLR1 heterodimer is very different from hTLR10 homodimer in which interactions occur between the BB-loop of TLR1 and DD-loop of TLR2 (24). Different interactions mainly occur between hydrophobic residues in the BB-loops and the αC-helices (25). Due to the exposure to the surrounding solvent, the BB-lope of TIR domain may be important to recruit adaptor protein (26). The evolutionary analysis of proteins has revealed that TLR10 has a more similar structure to hTLR1 and hTLR6 than other TLR molecules (27).

Distribution Of TLR10

The human TLR10 has been detected in plasmacytoid dendritic cells from peripheral blood B cells, B cell lines, and Dendritic Cells (DCs) subset derived from CD34+ progenitor cells (10, 28, 29). TLR10 is mainly restricted to B cells and has a role in B cell development and maturation.
Unlike naïve B cells, memory B cells express constitutively high levels of TLR10 along with low levels of TLR2, TLR4, and TLR8 (28). High level of expression of TLR10 is detected in immune tissues such as lymph node, lung, and spleen, where immune cells are abundant (31). Similar to peripheral blood B cells, the marginal zone B lymphocyte in normal spleen expresses a significant amount of TLR10 (32). While human TLR10 is not expressed in tonsillar plasma cells and hematopoietic stem cells (33, 34). Moreover, TLR10 is expressed on airway smooth muscle cells (ASMCs), trophoblast, and human placental tissue (6). Expression of TLR10 in smooth muscles in lungs and vascular endothelium of both inflamed and control animals (chickens, cattle, pigs, rats, and dogs) has been established in a research conducted by Balachandran Y et al. (35).

- **Function and Ligand**

  Human TLR10 is a largely functional receptor on surface B cells and pDCs which activates intracellular signaling pathway via MyD88 (10, 36, 37). No specific ligand has been identified for TLR10 (10). However, TLR10 in cooperation with TLR2 can identify triacylated lipopeptide agonists (38). Typical TLR-associated signaling pathway such as activation of NF-κB, production of interferon beta (IFN-β), or interleukin 8 (IL-8) could not be induced by hTLR10 (39). Resting B cells stimulation with *Staphylococcus aureus*, anti-CD40, and anti-human IgM (μ-chain specific) results in mRNA expression of both TLR9 and TLR10 [8]. In addition, cytosine-phosphate-guanine (CpG) DNA pattern can increase expression of TLR10 through potential positive regulation [48]. Moreover, the synthesized *Plasmodium falciparum* erythrocyte membrane protein 1-cysteine rich interdomain 1α (PfEMP1–CIDR1α) in a dose depended and lipopeptides could activate TLR10 similar to other members of the TLRs family, contained TIR domins [8, 49, 50].

  It is reported that stimulation of TLR10 by *Salmonella typhimurium* and *Listeria monocytogenes*, not heat killed bacteria, leads to the production of large amounts of IL-8 [13]. On the other hand, many studies have reported that involvement of TLR10 is not restricted to bacterial infection and it may sense component of influenza virus A, viral ribonucleoprotein (RNP), and double-stranded RNA (dsRNA), which triggers an innate immune response [15, 51, 52]. TLR10 recognizes human immunodeficiency virus-1 (HIV-1) proteins as a PAMP which resulting in IL-8 secretion via activation of NF-κB (40). It is reported by Jiang et al. that activation of TLR10 resulted in suppression of both myeloid differentiation primary response gene 88/TIR domain–containing adaptor inducing IFN-β (MyD88/TRIF)-dependent and independent signaling pathway in mononuclear cell, which inhibits production of inflammatory mediators, including IFN-β and interleukin 6 (37). B cell proliferation induced by S. aureus Cowan strain, a B cell mitogen, could be suppressed by TLR10 engagement (41). Also, the signal transduction, B cell proliferation, and cytokine production could be suppressed by antobody mediated- TLR10 ligation on primary human B cells (42). Anti-TLR10 antibodies can affect more than 30 genes such as activation induced cytosine deaminase (AICDA), chemokine ligand 3 (CCL3), and CCL4, involved in B cell signaling, migration, and immune function (18). However,
Hess NJ et al. have observed B cell development and antibody production in hTLR10 transgenic mice was not significant (43).

- **Proinflammatory and Anti-inflammatory Properties of TLR10**

All TLRs mediate their function via MyD88 and interleukin-1 receptor-associated kinase 4 (IRAK-4), except TLR3, which requires the signaling TRIF adaptor (44). The TLR2 and TLR4 heterodimers with TLR1, TLR6, and TLR10 invoke the TIR Domain Containing Adaptor Protein (TIRAP) adaptor (Figure 1), whereas TLR3, TLR7, TLR8, and TLR9 need UNC-93B (ubiquitinated-protein 93B) for proper intracellular localization (2). The signaling activity of TLR10 requires the downstream adapter molecule MyD88 which is usually engaged by other TLRs (6). The TLR10 antibody is able to suppress the phosphorylation of the mitogen-activated protein kinase (MAPK), JNK (c-Jun N-terminal kinases), but not P38 or extracellular signal-regulated kinases (ERKs) (6). Moreover, the anti-TLR10 antibodies are able to suppress Akt (Protein kinase B, PKB) signaling when stimulated with anti-B cell receptor antibody (αBCR), suggesting TLR10 may also be able to target the Phosphorus triiodide (PI3) kinase pathway (4). Increased expression of TLR7 and TLR10 was detected in B cells after stimulation by CIDR1α (cysteine-rich interdomain region 1α) and PfEMP1 from plasmodium falciparum. Furthermore, PfEMP1–CIDR1α recruits MYD88 and activates the downstream kinases such as IKBα ERK1/2 and p38 in human B cells (45). In a study conducted by Khoo JJ et al. the chimera receptor CD4-TLR10 can initiate the downstream signaling via NF-κB (46) which in turn leads to production of Tumor necrosis factor alpha (TNF-α) in macrophages (17). It has shown that NF-AT (nuclear factor of activated T cells) and forkhead box P3 (FOXP3) transcription factors regulate the expression of TLR10 in Tregs cells (47) and attenuates pro-inflammatory responses. Following the overexpression of TLR10 and TLR2 on the surface of HEK293 cells (a cell line derived from human embryonic kidney cells) initiates NF-κB activation, TNF-α, and IL-8 production upon ligation of TLR10 by helicobacter pylori (H. pylori) lipopolysaccharide (LPS) (18). Tim Regan et al. have reported that TLR10 knockdown reduced IL-8, CCL20 (C-C Motif Chemokine Ligand 20), and CCL1 in the THP-1 macrophage cell line. They also observed NF-κB activation in L. monocytogenes infected epithelial cells following ligation of TLR2 and TLR10 (48). In the rheumatoid arthritis (RA) patients, the IL-1β serum concentrations is significantly correlated with TLR10 expression on the CD19+CD27+ B cell subset, which is positively increased with disease activity (39, 49). Oxidative stress (H2O2) in patients with type-2 diabetes and obesity induces the TLR10 downstream pathways through MAPK/NF-κB signaling and increases the production of proinflammatory cytokines/chemokine IL-23A and CCL-5 (50).
Figure 1. The Inflammatory and Anti-inflammatory Signaling Pathways of TLR10. Occupation of TLR10 by its ligands (e.g., CPG-DNA, and dsRNA) initiates downstream signaling pathways via activation of adaptor molecules (e.g., MYD88) and transcriptional factors such as NF-κB and AP-1 which lead to the production of proinflammatory cytokines and chemokines (left). On the other hand, binding of TLR10 to the diverse ligands may inhibit MAPK downstream signaling or may activate PI3K (Right), which in turn inhibits the production of inflammatory mediators and production of IL-1Ra, an IL-1 receptor antagonist respectively.

Controversially, it is reported that production of proinflammatory cytokines increases by blocking TLR10 in human monocytes [44]. The engagement of TLR10 promotes the production of IL-1Ra, an anti-inflammatory cytokine, through TLR10-MAPK-dependent pathways [46]. A modulatory function of TLR10 has been reported by Mulla et al who found that the expressed TLR10 on trophoblastic cells induced apoptosis through recruitment of caspase-3 [35]. Two proteins, SIGIRR (single immunoglobulin interleukin-1 receptor-related protein) and interleukin 1 receptor-like 1 (ST2), have been shown to negatively regulate TLR signaling by sequestering the proximal adaptor MyD88 (4). Recent data demonstrated that knockdown of TLR10 by small hairpin RNA (shRNA) significantly upregulated the expression of IFN-β in response to poly immune complex (poly I: C) challenge. Also, blockage of TLR10 by neutralizing antibody
increases TNF-a, IL-6, and IL-8 secretion after microbial stimulation (48). The coexpression of TLR10 with TLR2 in HEK293 cells, resulting in reduction of IL-8 after bacterial or synthetic triacylated lipopeptide Pam3CSK4 challenge (51). Oosting et al also proposed that the inhibitory effect of TLR10 on IL-8 production is mainly through an autocrine or paracrine mechanism by the induction of IL-1Ra (IL-1 receptor antagonist), an endogenous antagonist for IL-1ß signaling (52). The silencing of TLR10 by RNA interference method leads to significant reduction in IL-8, CCL1 and CCL20 in the macrophage cell line THP-1 (16). Surprisingly, both thymus independent (TI) and thymus dependent (TD) antibody production are suppressed in TLR10 knock-in mouse model. Also, knockdown of TLR10 has shown suppressive effects on inflammation in the prostate tissue and RWPE-1 cell via downregulation of phospho-NF-κB P65, IL-6, and IL-8 (53). The monoclonal antibody against TLR10 on surface of mononuclear cells is able to suppress the production of proinflammatory cytokine, IL-6 (54).

- **TLR10 associated with diseases**

The relationship between TLR10 gene polymorphisms and diverse diseases has been already reported (Table 1). Theresa Neuper et al. have shown that engagement of TLR10 signaling pathway following H. Pylori infection reduces the production of inflammatory cytokines and chemokines, such as IL1-β (55). Similar results from studies in Chinese and European populations have confirmed a significant relationship between nonsynonymous single nucleotide polymorphism (SNP) of TLR10 (rs11096957) and severity of hip osteoarthritis (3, 40, 56). A population bearing a rare SNP rs4129009 in TLR10, which leads to the change from isoleucine to valine in the TIR domain of TLR10, has a decreased risk for developing atopic asthma (31, 57). TLR10–TLR1–TLR6 gene cluster analysis in patients with Crohn's disease (58) suggested that individuals with copies of TLR10GGGG, are more susceptible to Crohn's disease (59) (Table 1). Moreover, a study in New Zealander population has revealed that genetic variation in TLR10 may be associated with differences in susceptibility of Crohn's disease and clinical findings (60). Recently, it has been reported that individuals carrying TLR10 992T/A and 720A/C polymorphisms have no adequate immune response to Crimean-Congo hemorrhagic fever (61). On the other hand, Qiaoyan Xiang et al. have reported that the variant haplotype GAG is accompanied by higher level of IL-1β, IFN-γ, TNF-α in children with pneumococcal meningitis (62). Moreover, TLR10 gene polymorphisms among Korean population is associated with thyroid-associated ophthalmopathy, Hashimoto’s disease, and Graves' disease (63). Accordingly, another study has reported an effect of missense polymorphism of TLR10 in papillary thyroid carcinoma and tumor size in the Korean population (64). A distinct TLR10 mRNA expression profile was reported in mature B cell neoplasias, follicular lymphoma, multiple myeloma, Epstein Barr virus–transformed cell lines, and Burkitt lymphoma (5). Furthermore, similar to normal and activated B cells, this population expresses high levels of TLR10 in chronic lymphocytic leukemia (65). Ligation of TLR10 by PAMPs and ubiquitous inhaled
allergen in early life has a role in increasing asthma susceptibility (66). Accordingly, a health study cohort revealed a significant association between physician-diagnosed asthma among European American populations. These findings have provided strong support for risk of asthma and TLR10 genetic variation (67). Also, studies have confirmed the relationship between variants of TLR10 and increased risk of prostate cancer (68) and nasopharyngeal carcinoma (69).

Table 1. The properties of Some variation of TLR10 and susceptibility to disease

| Author        | Year | Polymorphism(s) | Population(s)                                      | Outcome(s)                                                                 |
|---------------|------|-----------------|---------------------------------------------------|----------------------------------------------------------------------------|
| Korppi M      | 2013 | Rs4129009       | Finnish Post bronchiolitis patients               | Association with asthma medication and asthma risk                         |
| 2 Kizildag    | 2017 | 922TT/AA        | Crimean Congo hemorrhagic fever patient           | Three times greater risk of AA genotype than TT genotype in patients with CCHF |
|               |      | 922TT/A & 2322A/G |                                                  | Association with patient mortality                                        |
|               |      | 922TT/A & 720A/C |                                                  | Association with pathogenesis of CCHF disease                               |
|               |      | 922AA           |                                                  | Decreased susceptibility of CCHF disease                                    |
|               |      | 720CC           |                                                  | Increased susceptibility of CCHF disease                                    |
| Tongtawee     | 2018 | Rs10004195      | Thai population                                   | Increased susceptibility to the pathogenesis of H. Pylori & gastric         |
| Vrgoc         | 2018 | Rs11096957      | Osteoarthritis patients and 597 controls from Croatian population | The association of the major alele (T) with lower and the minor allele(c) with higher risk for acquiring hip OA |
|               |      |                 |                                                  | Association of Genotype T/T with the protection to hip OA and genotype T/C with higher risk for acquiring hip OA |
| Won Kyoung    | 2014 | Rs4129009       | Korean AITD patients (Grave’s disease, Hashimoto disease, thyroid associated ophthalmopathy) | Association with prostate cancer and asthma                                |
|               |      | Rs10004195      |                                                  | Association with IgA nephropathy                                           |
|               |      | Rs11466653      |                                                  | Association with small tumor size PTC in Korean population                |
| Noulivirta et al. | 2016 | Rs4129009     | Full-term hospitalized infants for bronchiolitis at the age less than 6 months. | Association of TLR10rs4129009 minor allele G with elevated total serum IgE and rs4129009 allele with atopy |
| Lazarus et al. | 2004 | Single nucleotide polymorphisms (SNPs) | Case control study European American with diagnosed asthma | Association between two SNPs and physician-diagnosed asthma |
| Mikacenic     | 2012 | TLR10 genetic variation | Healthy Caucasian | A strong association between pam3CSK4-induced cytokines in inflammatory responses and genetic variation of the TLR1/6/10 |
| Jielin Sun    | 2006 |                 | prostate cancer patients and controls group in Sweden | Association of one single-nucleotide polymorphism in IRAK4 (Interleukin-1 receptor-associated kinases 4), in combination with the high-risk genotype at TLR6-1-10, and a significant increased risk of prostate cancer |
| J.Liu         | 2011 | TLR10 Rs4129009 | Neonates born in the Munich, Germany.             | Modified FOXP3 expression by TLR1 rs4833095 and trend like by TLR10 rs4129009 after LpA and Ppg  |
### Discussion

TLR10 is the new member of pattern-recognition receptor with an unspecified ligand and biologic function. Within the human TLR family, TLR1 and TLR6 are the most closely related to TLR10 (70). Hence, at first glance, TLR10 may have the same biological function as TLR1 and TLR6, whereas different investigations have controversially reported the inflammatory and anti-inflammatory properties for hTLR10. Some studies have disclosed TNF-α production in macrophages and B cells following the upregulation of TLR10 expression via MYD88 and NF-κB activation (65, 71). Moreover, H. pylori LPS ligation of TLR10 and TLR2 on the surface of HEK293 cells involves NF-κB and proinflammatory IL-8 and TNF-α production (72). In addition, induction of the TLR10 expression by oxidative stress in type-2 diabetes and obese patients leads to activation of MAPK/NF-κB signaling, which increases the production of proinflammatory cytokines/chemokine IL-23A and CCL-5 (73). On the other hand, induction of IL-1Ra following TLR10 involvement, is associated with impaired TLR10 function in Meniere disease, suggests an inflammatory function of TLR10 (74). However, the findings from study by Tim Regan et al have demonstrated that knockdown of TLR10 in the macrophage cell line THP-1 reduces IL-8, CCL20, 

|   | Author | Year | SNP | Summary |
|---|---|---|---|---|
| 11 | Heinzman A | 2010 |  | Genotyped polymorphisms in asthmatic children and controls |
| 12 | Beena Mailaparambil | 2010 | TLR10 rs11096955 | Infants born with a gestational age ≤ 28 at the tertiary neonatal center, Freiburg |
| 13 | Bouker KB | 2007 | A4396G | Breast cancer cell lines. |
| 14 | Ana M. Matascobos | 2015 | Rs4129009 | Acute pancreatitis patients / controls |
| 15 | Yen-ching Chen | 2007 |  | Patients with prostate cancer and controls without prostate cancer |
| 16 | Camila De Barros Gallo | 2017 | Rs11096957 | OSCC, LSCC, OLD, OLP, and OLL patients and healthy controls, from Spain. |
| 17 | Macarena Guirado | 2012 | TLR10 rs4129009 | Patients with urothelial bladder cell carcinoma in Spain. |
| 18 | Silvia Torices | 2016 | I473T variant | Patients with rheumatoid arthritis / controls subjects |

CCHF: Crimean Congo hemorrhagic fever; OA: Osteoarthritis; AITD: Autoimmune thyroid disease; Oscc: Oral squamous cell carcinoma; Lscc : Laryngeal squamous cell carcinoma; OLD: Oral lichenoid disease; OLP: Oral lichen planus ; OLL: Oral lichenoid lesions
and CCL1 (75). Overall, these data indicated the role of TLR10 in triggered inflammation responses. Oosting et al reported that TLR10-induced IL-8 production is inhibited by autocrine or paracrine effects of endogenous antagonist for IL-1β signaling, IL-1 receptor antagonist (IL-1Ra) (52). The anti-inflammatory aspect of TLR10 is inhibition of antibody production either thymus independent or dependent in TLR10 knock-in mouse model (54). Accordingly, production of proinflammatory cytokine, IL-6, is suppressed by monoclonal antibody against TLR10 in human monocyte cell line (42). Also, decreased IL-2 and IFN-γ production is reported by activate T cells co-cultured with TLR10 differentiated dendritic cells (42). The inhibitory and suppressive effects of human TLR10 are not fully surprising. Because the human TLR10 is a member of pattern recognition receptors and Toll/IL-1R family with well-defined inhibitory molecules (76). However, several key mutations within BB loop of the TIR domain of TLR10 may cause the inhibitory TLR signaling and anti-inflammatory properties (77, 78). Proinflammatory roles of TLR10 through ligation with live H5N1 flu virus infections, not heat-killed or UV-inactivated pathogens have been shown in a research conducted by Lee SM et al. They have been reported that knocking down TLR10 expression in THP-1 cell lines suppresses the production of proinflammatory cytokines (65). These findings suggest the increased proinflammatory cytokines and interferon following the overexpression of TLR10 by live Influenza virus infection (65). On the other hand, suppressing proinflammatory signaling pathways induced by antibody-mediated engagement of TLR10 leads to downregulation of proinflammatory cytokines. Also, the long-term ligation of TLR10 alone is also enough for the monocytes differentiation into dendritic cells, which is not capable of activating T lymphocytes cells (42). The TLR10 downstream signaling pathway is similar to other TLRs, including TIRAP, MyD88, TRIF, and TRIF related adaptor molecule (TRAM) (79), but the anti-inflammatory effects of TLR10 may be located in its intracellular structure. The activating or repressive role of TLR10 is related to several amino acids in the BB loop of this receptor. Recently, more TIR domain-containing proteins such as sterile alpha motif (46) and armadillo-motif-containing protein (80), ankyrin repeats-1 (81), and BCAP (B cell adaptor for PI3K) (82) have been described. Hence, studies have suggested a negative regulatory role through inhibition of MYD88/TRIF and PI3K/Akt signaling pathway (82, 83).

- **Conclusion**

The biological role of TLR10 has not yet been fully understood, and this may be due to the lack of identification of the ligand of this receptor. Recent studies have reported the suppressive role of TLR10 compared to its role in stimulating the inflammatory response which may be due to a series of adaptor proteins that have not been identified so far. Overall, the findings indicated that different genetic variations in TLR10 could affect the balance between inflammatory and anti-inflammatory responses. It can be concluded that this change may regulate the susceptibility to infection diseases or autoimmune disorders. In addition, the type and nature of antigen for instance ligation of TLR10 by live or killed infections may initiate pro-
or anti-inflammatory immune responses. There is a prospect for the development of novel immunotherapy strategies based on modulation of the function of TLR10. Nevertheless, comprehensive studies are needed to identify molecular and biological aspects of human TLR10.

- **Acknowledgments**
  This study was supported by grant No 98135 from Shahroud University of Medical Sciences.

- **Conflict of interests**
  The Authors declare that there is no conflict of interest

**References**

1. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature. 2000;406(6797):782-8.
2. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nature immunology. 2010;11(5):373.
3. Kaisho T, Akira S. Toll-like receptor function and signaling. Journal of allergy and clinical immunology. 2006;117(5):979-87.
4. Jafari R, Aflatoonian R, Falak R, Pourmand G, Dehghani S, Mortazavi M, et al. Down-regulation of inflammatory signaling pathways despite up-regulation of Toll-like receptors; the effects of corticosteroid therapy in brain-dead kidney donors, a double-blind, randomized, controlled trial. Molecular immunology. 2018;94:36-44.
5. Li X-D, Chen ZJ. Sequence specific detection of bacterial 23S ribosomal RNA by TLR13. Elife. 2012;1:e00102.
6. Mulla MJ, Myrtolli K, Tadesse S, Stanwood NL, Gariepy A, Guller S, et al. Cutting-Edge Report: TLR 10 Plays a Role in Mediating Bacterial Peptidoglycan-Induced Trophoblast Apoptosis. American journal of reproductive immunology. 2013;69(5):449-53.
7. Nagase H, Okugawa S, Ota Y, Yamaguchi M, Tomizawa H, Matsushima K, et al. Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand. The Journal of Immunology. 2003;171(8):3977-82.
8. Griffioen K, Mattson MP, Okun E. Deficiency of Toll-like receptors 2, 3 or 4 extends life expectancy in Huntington’s disease mice. Heliyon. 2018;4(1):e00508.
9. Silver AC, Buckley SM, Hughes ME, Hastings AK, Nitabach MN, Fikrig E. Daily oscillations in expression and responsiveness of Toll-like receptors in splenic immune cells. Heliyon. 2018;4(3):e00579.
10. Hasan U, Chaffois C, Gaillard C, Saulnier V, Merck E, Tancredi S, et al. Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. The Journal of Immunology. 2005;174(5):2942-50.
11. Hubert F-X, Voisine C, Louvet C, Heslan M, Josien R. Rat plasmacytoid dendritic cells are an abundant subset of MHC class II+ CD4+ CD11b− OX62− and type I IFN-producing cells that exhibit selective expression of Toll-like receptors 7 and 9 and strong responsiveness to CpG. The Journal of Immunology. 2004;172(12):7485-94.
12. Nalubamba KS, Gossner AG, Dalziel RG, Hopkins J. Differential expression of pattern recognition receptors in sheep tissues and leukocyte subsets. Veterinary immunology and immunopathology. 2007;118(3-4):252-62.
13. Opsal MA, Våge DI, Hayes B, Berget I, Lien S. Genomic organization and transcript profiling of the bovine toll-like receptor gene cluster TLR6-TLR1-TLR10. Gene. 2006;384:45-50.
14. Botos I, Segal DM, Davies DR. The structural biology of Toll-like receptors. Structure. 2011;19(4):447-59.
15. Lakshmi BBS, Kumar MP, Rao NR. World Journal of Pharmaceutical ReseaRch. 2015.
16. Faili A, Aoufouchi S, Guéranger Q, Zober C, Léon A, Bertocci B, et al. AID-dependent somatic hypermutation occurs as a DNA single-strand event in the BL2 cell line. Nature immunology. 2002;3(9):815.
17. Lee SM, Kok K-H, Jaume M, Cheung TK, Yip T-F, Lai JC, et al. Toll-like receptor 10 is involved in induction of innate immune responses to influenza virus infection. Proceedings of the National Academy of Sciences. 2014;201324266.
18. Weller S, Bonnet M, Delagreverie H, Israel L, Chrabieh M, Maródi L, et al. IgM+ IgD+ CD27+ B cells are markedly reduced in IRAK-4-, MyD88- and TIRAP-but not UNC-93B-deficient patients. Blood. 2012:blood-2012-07-440776.
19. Yip T-f. Characterization of an orphan receptor: sub-cellular localization, ligand identification and cellular events for signaling activation of toll-like receptor 10. HKU Theses Online (HKUTO). 2015.
20. Krutzik SR, Ochoa MT, Sieling PA, Uematsu S, Ng YW, Legaspi A, et al. Activation and regulation of Toll-like receptors 2 and 1 in human leprosy. Nature medicine. 2003;9(5):525.
21. Meijer AH, Krens SG, Rodriguez IAM, He S, Bitter W, Snaar-Jagalska BE, et al. Expression analysis of the Toll-like receptor and TIR domain adaptor families of zebrafish. Molecular immunology. 2004;40(11):773-83.
22. Nyman T, Stenmark P, Flodin S, Johansson I, Hammarström M, Nordlund P. The crystal structure of the human toll-like receptor 10 cytoplasmic domain reveals a putative signaling dimer. Journal of Biological Chemistry. 2008;283(18):11861-5.
23. O'neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunological reviews. 2008;226(1):10-8.
24. Gautam JK, Comeau LD, Krueger JK, Smith MF. Structural and functional evidence for the role of the TLR2 DD loop in TLR1/TLR2 heterodimerization and signaling. Journal of Biological Chemistry. 2006.
25. Gay NJ, Symmons MF, Gangloff M, Bryant CE. Assembly and localization of Toll-like receptor signalling complexes. Nature reviews Immunology. 2014;14(8):546.
26. Nimma S, Ve T, Williams SJ, Kobe B. Towards the structure of the TIR-domain signalosome. Current opinion in structural biology. 2017;43:122-30.
27. Kruithof EK, Satta N, Liu JW, Dunoyer-Geindre S, Fish RJ. Gene conversion limits divergence of mammalian TRL1 and TRL6. BMC evolutionary biology. 2007;7(1):148.
28. Bourke E, Bosio D, Golay J, Polentarutti N, Mantovani A. The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood. 2003;102(3):956-63.
29. Hartmann E, Wollenberg B, Rothenfusser S, Wagner M, Wellisch D, Mack B, et al. Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer research. 2003;63(19):6478-87.
30. Muzio M, Bertilaccio MT, Simonetti G, Frenquelli M, Caligaris-Cappio F. The role of Toll-like receptors in chronic B cell malignancies. Leukemia & lymphoma. 2009;50(10):1573-80.
31. Lazarus R, Raby BA, Lange C, Silverman EK, Kwiatkowski DJ, Vercelli D, et al. TOLL-like receptor 10 genetic variation is associated with asthma in two independent samples. American journal of respiratory and critical care medicine. 2004;170(6):594-600.
32. Meyer-Bahlburg A, Rawlings DJ. B cell autonomous TLR signaling and autoimmunity. Autoimmunity reviews. 2008;7(4):313-6.
33. Dorner M, Brandt S, Tinguely M, Zucol F, Bourquin JP, Zauner L, et al. Plasma cell toll-like receptor (TLR) expression differs from that of B cells, and plasma cell TLR triggering enhances immunoglobulin production. Immunology. 2009;128(4):573-9.
34. Liotta F, Angeli R, Cosmi L, Fili L, Manuelli C, Frosali F, et al. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem cells. 2008;26(1):279-89.

35. Balachandran Y, Knaus S, Caldwell S, Singh B. Toll-like receptor 10 expression in chicken, cattle, pig, dog, and rat lungs. Veterinary immunology and immunopathology. 2015;168(3-4):184-92.

36. Isnardi I, Ng Y-S, Srdanovic I, Motaghedi R, Rudchenko S, von Bernuth H, et al. IRAK-4- and MyD88-dependent pathways are essential for the removal of developing autoreactive B cells in humans. Immunity. 2008;29(5):746-57.

37. Jiang S, Li X, Hess NJ, Guan Y, Tapping RI. TLR10 is a negative regulator of both MyD88-dependent and-independent TLR signaling. The Journal of Immunology. 2016:1502599.

38. Mikacenic C, Reiner AP, Holden TD, Nickerson DA, Wurfel MM. Variation in the TLR10/TLR1/TLR6 locus is the major genetic determinant of interindividual difference in TLR1/2-mediated responses. Genes and immunity. 2013;14(1):52.

39. Guan Y, Ranoa DRE, Jiang S, Mutha SK, Li X, Baudry J, et al. Human TLRs 10 and 1 share common mechanisms of innate immune sensing but not signaling. The Journal of Immunology. 2010:ji_0901888.

40. Henrick BM, Yao X-D, Zahoor MA, Abimiku Al, Osawe S, Rosenthal KL. TLR10 senses HIV-1 proteins and significantly enhances HIV-1 infection. Frontiers in Immunology. 2019;10:482.

41. Sackmann A, Heiner M, Koch I. Application of Petri net based analysis techniques to signal transduction pathways. BMC bioinformatics. 2006;7(1):482.

42. Hess NJ, Felicelli C, Grage J, Tapping RIJJolb. TLR10 suppresses the activation and differentiation of monocytes with effects on DC-mediated adaptive immune responses. 2017;101(5):1245-52.

43. Hess NJ, Jiang S, Li X, Guan Y, Tapping RI. TLR10 is a B cell intrinsic suppressor of adaptive immune responses. The Journal of Immunology. 2017;198(2):699-707.

44. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature. 2000;406(6797):782.

45. Lai C-Y, Yu G-Y, Luo Y, Xiang R, Chuang T-H. Immunostimulatory activities of CpG-Oligodeoxynucleotides in teleosts: Toll-like receptors 9 and 21. Frontiers in immunology. 2019;10.

46. Khoo JJ, Forster S, Mansell A. Toll-like receptors as interferon-regulated genes and their role in disease. Journal of Interferon & Cytokine Research. 2011;31(1):13-25.

47. Bell MP, Svingen PA, Rahman MK, Xiong Y, Faubion WA. Forkhead Box P3 regulates TLR10 expression in human T regulatory cells. The Journal of Immunology. 2007;179(3):1893-900.

48. Oosting M, Cheng S-C, Bolscher JM, Vestering-Stenger R, Plantinga TS, Verschueren IC, et al. Human TLR10 is an anti-inflammatory pattern-recognition receptor. Proceedings of the National Academy of Sciences. 2014;111(42):E4478-E84.

49. Kumar V. Going, Toll-like receptors in skin inflammation and inflammatory diseases. EXCLI journal. 2021;20:52.

50. Bergman I-M, Rosengren JK, Edman K, Edfors I. European wild boars and domestic pigs display different polymorphic patterns in the Toll-like receptor (TLR) 1, TLR2, and TLR6 genes. Immunogenetics. 2010;62(1):49-58.

51. Stappers MH, Oosting M, Ioana M, Reimmnitz P, Mouton JW, Netea MG, et al. Genetic variation in TLR10, an inhibitory Toll-like receptor, influences susceptibility to complicated skin and skin structure infections. The Journal of infectious diseases. 2015;212(9):1419-9.

52. Oosting M, Cheng S-C, Bolscher JM, Vestering-Stenger R, Plantinga TS, Verschueren IC, et al. Human TLR10 is an anti-inflammatory pattern-recognition receptor. 2014;111(42):E4478-E84.

53. Fan Y, Yang L, Wei Q, Ding Y, Tang Z, Tan P, et al. Toll-like receptor 10 (TLR10) exhibits suppressive effects on inflammation of prostate epithelial cells. Asian journal of andrology. 2019;21(4):393.
54. Regan T, Nally K, Carmody R, Houston A, Shanahan F, MacSharry J, et al. Identification of TLR10 as a key mediator of the inflammatory response to Listeria monocytogenes in intestinal epithelial cells and macrophages. 2013;191(12):6084-92.
55. Neuper T, Frauenlob T, Sarajlic M, Posselt G, Wessler S, Herejs-Hoek J. TLR2, TLR4 and TLR10 Shape the Cytokine and Chemokine Release of H. pylori-Infected Human DCs. International journal of molecular sciences. 2020;21(11):3897.
56. Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunological reviews. 2018;281(1):8-27.
57. Kormann MS, Depner M, Hartl D, Klopp N, Illig T, Adamski J, et al. Toll-like receptor heterodimer variants protect from childhood asthma. Journal of Allergy and Clinical Immunology. 2008;122(1):86-92.
58. McDonald DR, Geha RS. Human Immunodeficiencies Resulting From Defective NF-κB Activation. Stiehm's Immune Deficiencies: Elsevier; 2015. p. 665-86.
59. Abad C, Gonzalez-Escribano M, Diaz-Gallo L, Lucona-Soto J, Márquez J, Leo E, et al. Association of Toll-like receptor 10 and susceptibility to Crohn's disease independent of NOD2. Genes and immunity. 2011;12(8):635.
60. Morgan AR, Lam W-J, Han D-Y, Fraser AG, Ferguson LR. Genetic variation within TLR10 is associated with Crohn's disease in a New Zealand population. Human immunology. 2012;73(4):416-20.
61. Kızıldağ S, Arslan S, Özbilüm N, Engin A, Bakır MJ Jomv. Effect of TLR10 (2322A/G, 720A/C, and 992T/A) polymorphisms on the pathogenesis of Crimean Congo hemorrhagic fever disease. 2018;90(1):19-25.
62. Xiang Q, Zhu L, Zheng K, Ding Y, Chen N, Liu G, et al. Association of toll-like receptor 10 polymorphisms with pediatric pneumococcal meningitis. Apmis. 2020;128(4):335-42.
63. Cho WK, Jang J-P, Choi E-J, Jeon YJ, Jung IA, Kim S-H, et al. Association of Toll-like receptor 10 polymorphisms with autoimmune thyroid disease in Korean children. 2015;25(2):250-5.
64. Guan Y, Ranoa DRE, Jiang S, Mutha SK, Li X, Baudry J, et al. Human TLRs 10 and 1 share common mechanisms of innate immune sensing but not signaling. 2010;184(9):5094-103.
65. Chuang T-H, Ulevitch RJJBeBA-GS, Expression. Identification of hTLR10: a novel human Toll-like receptor preferentially expressed in immune cells. 2001;1518(1-2):157-61.
66. Hasan U, Chaffois C, Gaillard C, Saulnier V, Merck E, Tancredi S, et al. Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. 2005;174(5):2942-50.
67. Nagashima H, Iwatani S, Cruz M, Jiménez Abreu JA, Uchida T, Mahachai V, et al. Toll-like receptor 10 in Helicobacter pylori infection. 2015;212(10):1666-76.
68. Sindhu S, Akhter N, Kochumon S, Thomas R, Wilson A, Shenouda S, et al. Increased expression of the innate immune receptor TLR10 in obesity and type-2 diabetes: association with ROS-mediated oxidative stress. 2018;45(2):572-90.
74. Dinarello CA, Simon A, Van Der Meer JW Jr. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. 2012;11(8):633.
75. Regan T, Nally K, Carmody R, Houston A, Shanahan F, MacSharry J, et al. Identification of TLR10 as a key mediator of the inflammatory response to Listeria monocytogenes in intestinal epithelial cells and macrophages. The Journal of Immunology. 2013;191(12):6084-92.
76. Medzhitov R, Janeway Jr CJ. The Toll receptor family and microbial recognition. 2000;8(10):452-6.
77. Mikami T, Miyashita H, Takatsuka S, Kuroki Y, Matsushima NJ. Molecular evolution of vertebrate Toll-like receptors: evolutionary rate difference between their leucine-rich repeats and their TIR domains. 2012;503(2):235-43.
78. Roach JC, Glusman G, Rowen L, Kaur A, Purcell MK, Smith KD, et al. The evolution of vertebrate Toll-like receptors. 2005;102(27):9577-82.
79. Kondo T, Kawai T, Akira SJ. Dissecting negative regulation of Toll-like receptor signaling. 2012;33(9):449-58.
80. Panneerselvam P, Ding JJ. Beyond TLR signaling—the role of SARM in antiviral immune defense, apoptosis & development. 2015;34(5):432-44.
81. Wu Y-Y, Kumar R, Iida R, Bagavant H, Alarcón-Riquelme ME. BANK1 regulates IgG production in a lupus model by controlling TLR7-dependent STAT1 activation. 2016;11(5):e0156302.
82. Troutman TD, Hu W, Fulenchek S, Yamazaki T, Kurosaki T, Bazan JF, et al. Role for B-cell adapter for PI3K (BCAP) as a signaling adapter linking Toll-like receptors (TLRs) to serine/threonine kinases PI3K/Akt. 2012;109(1):273-8.
83. Carty M, Goodbody R, Schröder M, Stack J, Moynagh PN, Bowie AG. The human adaptor SARM negatively regulates adaptor protein TRIF–dependent Toll-like receptor signaling. 2006;7(10):1074.